PHILADELPHIA, August 6, 2025 — Leads & Copy — Context Therapeutics Inc. (Nasdaq: CNTX) reported its second quarter financial results, showing cash and cash equivalents of $83.5 million as of June 30, 2025. The company anticipates these funds will support operations into 2027. CTIM-76 and CT-95 Phase 1 dose-escalation studies are ongoing.
According to CEO Martin Lehr, the company is focused on advancing its clinical pipeline, which includes CTIM-76, a selective Claudin 6 x CD3 bispecific antibody, and CT-95, an avidity enhanced mesothelin x CD3 bispecific antibody. Initial dose escalation data for the CTIM-76 trial is expected in the second quarter of 2026, with CT-95 trial data anticipated by mid-2026.
The company also plans to complete regulatory filings for a first-in-human trial for CT-202, a Nectin-4 x CD3 bispecific antibody, in the second quarter of 2026.
Second quarter highlights included a Trial in Progress poster presentation for CTIM-76 at the ASCO Annual Meeting in June 2025, and preclinical data presentations for CT-95 at the AACR Annual Meeting 2025 in April 2025. The first patient was dosed in the Phase 1 clinical trial for CT-95 in April 2025. Dr. Karen Chagin was appointed Chief Medical Officer in June 2025.
R&D expenses for the second quarter of 2025 were $7.8 million, compared to $1.4 million for the same period in 2024. The company reported a net loss of $8.8 million for the second quarter of 2025, compared to a loss of $2.3 million for the second quarter of 2024.
Investor Relations Contact: Jennifer Minai-Azary, IR@contexttherapeutics.com
Source: Context Therapeutics Inc.
